OTCMKTS:LZAGY - Lonza Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$60.68
▼ -0.91 (-1.48%)
1 month | 3 months | 12 months
Get New Lonza Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LZAGY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LZAGY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Lonza Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $60.68.
Buy
The current consensus among 6 polled investment analysts is to buy stock in Lonza Group. This rating has held steady since June 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/12/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/3/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
11/11/2020UBS GroupReiterated RatingNeutral
i
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight
i
10/21/2020Societe GeneraleReiterated RatingBuy
i
10/2/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
i
9/14/2020Morgan StanleyReiterated RatingOverweight
i
9/4/2020Societe GeneraleReiterated RatingBuy
i
8/13/2020Credit Suisse GroupReiterated RatingOutperform
i
7/30/2020Morgan StanleyReiterated RatingOverweight
i
7/8/2020UBS GroupReiterated RatingNeutral
i
6/24/2020Morgan StanleyReiterated RatingOverweight
i
5/14/2020UBS GroupDowngradeBuy ➝ Neutral
i
1/31/2019Bank of AmericaDowngradeBuy ➝ Neutral
i
7/19/2017Jefferies Financial GroupUpgradeHold ➝ Buy
i
12/11/2015UBS GroupDowngradeNeutral
i
(Data available from 12/3/2015 forward)
Lonza Group logo
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma Biotech & Nutrition, and Specialty Ingredients. The Pharma Biotech & Nutrition segment provides technology platforms, including drug substance and drug product; and develops and manufactures customized active pharmaceutical ingredients and biopharmaceuticals, as well as formulation services and delivery systems for pharmaceutical and nutritional applications. It serves pharmaceutical companies, biotechnology firms, and medical research and testing organizations, as well as consumer health and nutrition companies. The Specialty Ingredients segment operates microbial control solutions and specialty chemical services businesses. Its Microbial control solutions business has offerings in professional hygiene, and home and personal care markets; and offerings in paints and coating, wood protection, material protection, and crop protection. This segments also offers specialty chemicals in electronics, aerospace, food and feed ingredients, agro chemicals, and diversified specialty chemicals markets. The company has collaboration with Moderna, Inc. to manufacture a potential COVID-19 vaccine, mRNA-1273. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
Read More

Today's Range

Now: $60.68
$60.42
$60.99

50 Day Range

MA: $63.66
$60.41
$68.66

52 Week Range

Now: $60.68
$32.09
$68.99

Volume

110,509 shs

Average Volume

105,831 shs

Market Capitalization

$45.19 billion

P/E Ratio

44.29

Dividend Yield

0.34%

Beta

0.75